NPX-267

N/A

Report date: 2025/06/28 20:00:07
First In Class

Base Information

Drug NameNPX-267
Drug Alias NameNPX-267
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionKiller cell immunoglobulin-like receptor 3DL3 inhibitors
TargetsKiller cell immunoglobulin-like receptor 3DL3
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesNextPoint Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNextPoint Therapeutics Inc
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A